Sparsentan
Focal Segmental Glomerulosclerosis (FSGS)
Phase 3Late-stage clinical development
Key Facts
Indication
Focal Segmental Glomerulosclerosis (FSGS)
Phase
Phase 3
Status
Late-stage clinical development
Company
About Travere Therapeutics
Travere Therapeutics is a publicly traded biopharma company singularly focused on rare diseases, particularly in nephrology and metabolism. Its strategic pipeline includes the commercially available therapy for IgA nephropathy and late-stage investigational candidates for FSGS and classical homocystinuria, aiming to set new standards of care. The company operates with a deep sense of urgency, guided by its 'In Rare For Life' ethos and a leadership team that includes rare disease patients and survivors, fostering strong community and advocacy partnerships.
View full company profileTherapeutic Areas
Other Focal Segmental Glomerulosclerosis (FSGS) Drugs
| Drug | Company | Phase |
|---|---|---|
| voclosporin | Aurinia Pharmaceuticals | Phase 2 |